circLPAR1 is a novel biomarker of prognosis for muscle‑invasive bladder cancer with invasion and metastasis by miR‑762

  • Authors:
    • Guowen Lin
    • Haoyue Sheng
    • Huyang Xie
    • Qiupeng Zheng
    • Yijun Shen
    • Guohai Shi
    • Dingwei Ye
  • View Affiliations

  • Published online on: January 25, 2019     https://doi.org/10.3892/ol.2019.9970
  • Pages: 3537-3547
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Circular RNAs (circRNAs) are a specific form of non‑coding RNAs, that serve a pivotal role in the development of human diseases, including Alzheimer's disease and cancer; however, only a few are known with respect to cancer. The present study identified a novel circRNA, circ lysophosphatidic acid receptor 1 (LPAR1) (hsa_circ_0087960), derived from two exons 226 base pairs in length, in muscle‑invasive bladder cancer (MIBC) tissues. circLPAR1 was identified to be lowly expressed in MIBC tissues in a cohort of 125 cases, and predicted a poor disease‑specific survival time, compared with patients with high circLPAR1 expression (52.4 vs. 56.0 months; P=0.001) by univariate and multivariate Cox regression analyses. Matrigel and wound healing assays also demonstrated that the invasion of 5637 and T24 bladder cancer cells were significantly enhanced following the knockdown of circLPAR1 by small interfering RNA (si‑circLPAR1‑1 in T24 cell line, P=0.01; si‑circLPAR1‑2 in 5637 cell line, P=0.003; si‑circLPAR1‑2 in T24 cell line, P=0.002; si‑circLPAR1‑2 in 5637 cell line, P=0.006). The bioinformatics analysis indicated that circLPAR1 may harbor specific microRNAs (miRNAs) according to the miRNAs seed sequence matching. A luciferase reporter assay revealed that miR‑762 can inhibit the activity of the transfected luciferase gene when inserted in a circLPAR1 wild‑type fragment, and this inhibition could be alleviated when the luciferase gene was inserted in a circLPAR1 fragment with the mutated miR‑762 target site. In conclusion, the circLPAR1 may function as a potential novel and stable biomarker for the prognosis of MIBC and may be associated with the invasion and metastasis by miR‑762.
View Figures
View References

Related Articles

Journal Cover

March-2019
Volume 17 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lin G, Sheng H, Xie H, Zheng Q, Shen Y, Shi G and Ye D: circLPAR1 is a novel biomarker of prognosis for muscle‑invasive bladder cancer with invasion and metastasis by miR‑762. Oncol Lett 17: 3537-3547, 2019
APA
Lin, G., Sheng, H., Xie, H., Zheng, Q., Shen, Y., Shi, G., & Ye, D. (2019). circLPAR1 is a novel biomarker of prognosis for muscle‑invasive bladder cancer with invasion and metastasis by miR‑762. Oncology Letters, 17, 3537-3547. https://doi.org/10.3892/ol.2019.9970
MLA
Lin, G., Sheng, H., Xie, H., Zheng, Q., Shen, Y., Shi, G., Ye, D."circLPAR1 is a novel biomarker of prognosis for muscle‑invasive bladder cancer with invasion and metastasis by miR‑762". Oncology Letters 17.3 (2019): 3537-3547.
Chicago
Lin, G., Sheng, H., Xie, H., Zheng, Q., Shen, Y., Shi, G., Ye, D."circLPAR1 is a novel biomarker of prognosis for muscle‑invasive bladder cancer with invasion and metastasis by miR‑762". Oncology Letters 17, no. 3 (2019): 3537-3547. https://doi.org/10.3892/ol.2019.9970